In a recent clinical trial, the use of sirolimus, a mammalian Target of Rapamycin (mTOR) inhibitor, reduced the circulating number of fibrocytes in IPF patients [59]. The gene discussed is MTOR; the disease is idiopathic pulmonary fibrosis.